Illumina / GRAIL

GRAIL's Galleri test represents a new category: screening healthy people for multiple cancers from a blood draw. It depends on advanced sequencing technology.

Illumina already controlled much of the sequencing hardware market. Enforcers feared rival test developers would hesitate to invest if their supplier also competed against them.

The FTC and European Commission pursued divestiture despite Illumina offering behavioral firewalls. EU authorities imposed a record-breaking fine for implementing the merger before clearance.

After losing appeals, Illumina spun GRAIL off again, illustrating how vertical mergers in essential inputs can face tough scrutiny even without a direct consumer brand clash.

Healthcare innovation can turn on access to shared platforms like sequencers or lab networks.

Vertical merger enforcement revived globally after being relatively quiet for years.

Parallel US and EU opposition signaled coordinated concern about platform foreclosure.

The merger would lessen competition in MCED test markets.

Illumina could foreclose rivals needing its sequencing systems.

Behavioral remedies were inadequate for protecting future innovation.

Illumina argued the merger accelerated life-saving screening access.

It proposed access commitments and firewalls to protect rivals.

Illumina said regulators underestimated competition from other sequencing and test platforms.

Cancer screening competition may depend on neutral access to lab technology.

The case shows enforcers will unwind closed deals if they believe harm is likely.

Patients may see multiple test providers only if platform access stays open.